Conformational Toggle Switches Implicated in Basal Constitutive and Agonist-induced Activated States of 5-hydroxytryptamine-4 Receptors
Overview
Pharmacology
Authors
Affiliations
The extended classic ternary complex model predicts that a G protein-coupled receptor (GPCR) exists in only two interconvertible states: an inactive R, and an active R(*). However, different structural active R(*) complexes may exist in addition to a silent inactive R ground state (Rg). Here we demonstrate, in a cellular context, that several R(*) states of 5-hydroxytryptamine-4 (5-HT(4)) receptors involve different side-chain conformational toggle switches. Using site-directed mutagenesis and molecular modeling approaches, we show that the basal constitutive receptor (R(*)basal) results from stabilization of an obligatory double toggle switch (Thr3.36 from inactive g- to active g+ and Trp6.48 from inactive g+ to active t). Mutation of either threonine or tryptophan to alanine resulted in a lowering of the activity of the R(*)basal similar to the Rg. The T3.36A mutation shows that the Thr3.36 toggle switch plays a minor role in the stabilization of R(*) induced by 5-HT (R(*)-5-HT) and BIMU8 (R(*)-BIMU8) and is fully required in the stabilization of R(*) induced by (S)-zacopride, cisapride, and 1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-butyl-4-piperidinyl)-1-propanone (RS 67333) (R(*)-benzamides). Thus, benzamides stabilize R(*)-benzamides by forming a specific hydrogen bond with Thr3.36 in the active g+ conformation. Conversely, R(*)-BIMU8 was probably the result of a direct conformational transition of Trp6.48 from inactive g+ to active t by hydrogen bonding of this residue to a carboxyl group of BIMU8. We were surprised that the Trp6.48 toggle switch was not necessary for receptor activation by the natural agonist 5-HT. R(*)-5-HT is probably attained through other routes of activation. Thus, different conformational arrangements occur during stabilization of R(*)basal, R(*)-5-HT, R(*)-benzamides, and R(*)-BIMU8.
Trotta R, Harmon D, Klotz J Physiol Rep. 2024; 12(13):e16128.
PMID: 38946059 PMC: 11214916. DOI: 10.14814/phy2.16128.
Llinas Del Torrent C, Raich I, Gonzalez A, Casajuana-Martin N, Lillo J, Rebassa J J Chem Inf Model. 2023; 63(18):5927-5935.
PMID: 37644761 PMC: 10523433. DOI: 10.1021/acs.jcim.3c01054.
Belinskaia D, Voronina P, Krivorotov D, Jenkins R, Goncharov N Pharmaceutics. 2023; 15(8).
PMID: 37631373 PMC: 10459044. DOI: 10.3390/pharmaceutics15082159.
Navarro G, Gonzalez A, Campanacci S, Rivas-Santisteban R, Reyes-Resina I, Casajuana-Martin N Comput Struct Biotechnol J. 2020; 18:2723-2732.
PMID: 33101610 PMC: 7550916. DOI: 10.1016/j.csbj.2020.09.028.
Ligand chain length drives activation of lipid G protein-coupled receptors.
Troupiotis-Tsailaki A, Zachmann J, Gonzalez-Gil I, Gonzalez A, Ortega-Gutierrez S, Lopez-Rodriguez M Sci Rep. 2017; 7(1):2020.
PMID: 28515494 PMC: 5435731. DOI: 10.1038/s41598-017-02104-5.